Literature DB >> 19434741

Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network.

Kristin David1, Kris V Kowdley, Aynur Unalp, Fasiha Kanwal, Elizabeth M Brunt, Jeffrey B Schwimmer.   

Abstract

UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States. The association between NAFLD and quality of life (QOL) remains unclear. These data are important to estimate the burden of illness in NAFLD. The aim was to report QOL scores of adults with NAFLD and examine the association between NAFLD severity and QOL. QOL data were collected from adults with NAFLD enrolled in the Nonalcoholic Steatohepatitis Clinical Research Network using the Short Form 36 (SF-36) survey, and scores were compared with normative U.S. population scores. Liver biopsy histology was reviewed by a central pathology committee. A total of 713 subjects with NAFLD (male = 269, female = 444) were included. Mean age of subjects was 48.3 years; 61% had definite nonalcoholic steatohepatitis (NASH), and 28% had bridging fibrosis or cirrhosis. Diabetes was present in 27% of subjects. Subjects with NAFLD had worse physical (mean, 45.2) and mental health scores (mean, 47.6) compared with the U.S. population with (mean, 50) and without (physical, 55.8; mental, 52.5) chronic illness. Subjects with NASH reported lower physical health compared with subjects with fatty liver disease without NASH (44.5 versus 47.1, P = 0.02). Subjects with cirrhosis had significantly (P < 0.001) poorer physical health scores (38.4) than subjects with no (47.6), mild (46.2), moderate (44.6), or bridging fibrosis (44.6). Cirrhosis was associated with poorer physical health after adjusting for potential confounders. Mental health scores did not differ between participants with and without NASH or by degree of fibrosis.
CONCLUSION: Adults with NAFLD have a significant decrement in QOL. Treatment of NAFLD should incorporate strategies to improve QOL, especially physical health.

Entities:  

Mesh:

Year:  2009        PMID: 19434741      PMCID: PMC2692572          DOI: 10.1002/hep.22868

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  51 in total

1.  Clinical significance of patient-reported questionnaire data: another step toward consensus.

Authors:  Jeff A Sloan; David Cella; Ron D Hays
Journal:  J Clin Epidemiol       Date:  2005-10-13       Impact factor: 6.437

2.  Estimating utility values for health states of overweight and obese individuals using the SF-36.

Authors:  Michael A Kortt; Philip M Clarke
Journal:  Qual Life Res       Date:  2005-12       Impact factor: 4.147

3.  Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.

Authors:  Herbert L Bonkovsky; Kristin K Snow; Peter F Malet; Carla Back-Madruga; Robert J Fontana; Richard K Sterling; Clark C Kulig; Adrian M Di Bisceglie; Timothy R Morgan; Jules L Dienstag; Marc G Ghany; David R Gretch
Journal:  J Hepatol       Date:  2006-11-27       Impact factor: 25.083

Review 4.  Interpretation of quality of life changes.

Authors:  E Lydick; R S Epstein
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

5.  Evaluation of fatigue in U.S. patients with primary biliary cirrhosis.

Authors:  Carmen M Stanca; Nancy Bach; Cynthia Krause; Nidhi Tandon; Maria A Freni; Julio A Gutierrez; Carol Bodian; Jose Lopez; Paul D Berk; Henry C Bodenheimer; Andrea D Branch; Joseph A Odin
Journal:  Am J Gastroenterol       Date:  2005-05       Impact factor: 10.864

6.  Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C.

Authors:  K B Hussain; R J Fontana; C A Moyer; G L Su; N Sneed-Pee; A S Lok
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

7.  Fatigue as a major predictor of quality of life in women with autoimmune liver disease: the case of primary biliary cirrhosis.

Authors:  Ellen D Sogolow; Judith N Lasker; Lynn M Short
Journal:  Womens Health Issues       Date:  2008-04-16

8.  Quality of life in patients with primary biliary cirrhosis.

Authors:  Renée Eugénie Poupon; Yves Chrétien; Olivier Chazouillères; Raoul Poupon; Judith Chwalow
Journal:  Hepatology       Date:  2004-08       Impact factor: 17.425

9.  Health-related quality of life in chronic hepatitis B patients.

Authors:  Siew Chin Ong; Belinda Mak; Myat Oo Aung; Shu-Chuen Li; Seng-Gee Lim
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

10.  The prevalence and etiology of elevated aminotransferase levels in the United States.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  60 in total

1.  Metabolic Syndrome Is Associated with Health-Related Quality of Life in Suspected Patients with Nonalcoholic Steatohepatitis.

Authors:  Ali Gholami; Farhad Zamani; Bayan Hosseini; Rahim Sharafkhani; Mansooreh Maadi; Zahra Moosavi Jahromi; Maryam Khazaee-Pool; Masoudreza Sohrabi
Journal:  Med Princ Pract       Date:  2018-02-05       Impact factor: 1.927

2.  Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial.

Authors:  Shira Zelber-Sagi; Assaf Buch; Hanny Yeshua; Nahum Vaisman; Muriel Webb; Gil Harari; Ofer Kis; Naomi Fliss-Isakov; Elena Izkhakov; Zamir Halpern; Erwin Santo; Ran Oren; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Cost-utility analysis of nonalcoholic steatohepatitis screening.

Authors:  Eric Zhang; Claire Wartelle-Bladou; Luigi Lepanto; Jean Lachaine; Guy Cloutier; An Tang
Journal:  Eur Radiol       Date:  2015-05-21       Impact factor: 5.315

4.  Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.

Authors:  Yuval A Patel; Joanne C Imperial; Andrew J Muir; Quentin M Anstee; David DeBrota; Lara Dimick-Santos; Claudia Filozof; Ruby Mehta; Arun J Sanyal; Elmer Schabel; Brent A Neuschwander-Tetri; Veronica Miller
Journal:  Gastroenterology       Date:  2017-07-27       Impact factor: 22.682

5.  Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease.

Authors:  Kristin D Kistler; Elizabeth M Brunt; Jeanne M Clark; Anna Mae Diehl; James F Sallis; Jeffrey B Schwimmer
Journal:  Am J Gastroenterol       Date:  2011-01-04       Impact factor: 10.864

6.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

7.  Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

Authors:  Shira Zelber-Sagi; Muriel Webb; Nimer Assy; Laurie Blendis; Hanny Yeshua; Moshe Leshno; Vlad Ratziu; Zamir Halpern; Ran Oren; Erwin Santo
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

8.  Nonalcoholic fatty liver disease: Disease and comorbidity--effects on quality of life.

Authors:  Giulio Marchesini; Giampaolo Bianchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

Review 9.  Shared symptoms and putative biological mechanisms in chronic liver disease: implications for biobehavioral research.

Authors:  Victoria Menzies; Nancy Jallo; Patricia Kinser; Jo Lynne W Robins; Kyungeh An; Carolyn Driscoll; Angela Starkweather; Jasmohan S Bajaj; Debra E Lyon
Journal:  Biol Res Nurs       Date:  2014-07-18       Impact factor: 2.522

10.  Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease.

Authors:  K D Kistler; J Molleston; A Unalp; S H Abrams; C Behling; J B Schwimmer
Journal:  Aliment Pharmacol Ther       Date:  2009-10-23       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.